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Introduction
Galectins are a family of ancient animal carbohydrate
binding proteins; the name is from their description as
β-galactoside-specific lectins. They have been strongly
implicated in inflammation and cancer and may be use-
ful as targets for the development of new anti-inflam-
matory and anti-cancer therapies (reviewed in [1]). 
Galectins are present at high concentration in a lim-
ited range of cell types, different for each galectin.
They bind to sugar molecules on the surface of cells.
All galectins bind lactose and other β galactosides, but
they differ in their affinity for more complex saccha-
rides [2]. The galectins are defined by their structural
similarities in their carbohydrate recognition domains
(CRD) and by their affinity for β-galactosides. They
have been classified into three classes, prototype,
chimera, and tandem-repeat galectins (reviewed in [1]). 
The only chimera galectin currently identified is
galectin-3 which contains one CRD connected to 
a non-lectin domain; in addition to the CRD it contains
a prolineand glycine-rich N-terminal domain (ND)
through which is able to form oligomers [3-5].
Galectin-3 is also called Mac-2, L29, CBP35 or εBP,
and is expressed in tumour cells (reviewed in [6]),
macrophages [7], activated T cells [8], certain 
epithelial cells [9] and fibroblasts [10]. It binds a vari-
ety of matrix glycoproteins including laminin and
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fibronectin [11]. Intracellularly, galectin-3 acts to pre-
vent apoptosis [reviewed in [1]). Depending on the cell
type, galectin-3 can be localized in the extracellular
matrix, the cell surface, in the cytoplasm, or in the
nucleus (reviewed in [1]). Galectin-3 has been shown
to exhibit pro-inflammatory activities in vitro and in
vivo; it induces pro-inflammatory and inhibits 
Th2 type cytokine production (reviewed in [1]). High
levels of circulating galectin-3 have been shown to
correlate with the malignancy potential of several
types of cancer. Galectin-3 is known to play a role in
tumour growth, metastasis, and cell-to-cell adhesion
(reviewd in [6]). It also serves as a preferred substrate
for matrix metalloproteinase-9 [12]. Finally, human
and mouse galectin-3 share approximately 80%
homology in their amino acid sequence [13]. 
The expression of galectin-3 is well known in ani-
mal urinary systems. In a normal rat kidney, it is
expressed in epithelial cells of distal tubules [14,15].
Interestingly, in a rat model of acute mesangial prolif-
erative glomerulonephritis [14], galectin-3 expression
was found increased in distal tubules, as well as in
glomerular macrophages, mesangial cells and proxi-
mal tubules. The similar pattern, except of mesangium
and glomerular macrophages was observed in 
a ischaemia/reperfusion renal failure model in rats.
Galectin-3 expression increased in proximal and distal
tubuli at 2 – 48 h after reperfusion and was then fol-
lowed by a normalization of the increased expression
[15]. Therefore, those findings were considered to be
acute reactions. On the other hand, in the study of
streptozotocin-induced rat diabetes, galectin-3 expres-
sion in glomeruli was observed at 2 months after injury
[16]. In the murine urinary system galectin-3 was
expressed continuously from the kidney to the distal
end of the urethra. The renal cortex expressed galectin-
3 more intensely than the medulla. Renal galectin-3
immunoreactivity was strongest in the cortical collect-
ing ducts, where principal cells were the sole cellular
source.
Studies of the association of galectins with various
aspects of kidney disease in humans are still at an early
stage [17-20]. In children with primary glomeru-
lonephritis, proteinuria is an important risk factor for
the progression of glomerular disease and follows both
qualitative and quantitative alterations in podocytes
and the glomerular architecture [21]. The concept that
podocytes, rather than mesangial cells, are the major
culprit in the progression of glomerular diseases is
gaining ground. In patients with nephrotic syndrome
(NS), proteinuria (> 50 mg/kg per 24 h) and progres-
sive loss of renal function are often mixed with tubu-
lar proteinuria superimposed on the underlying
glomerular pattern [22]. This is most typical of focal
segmental glomerulosclerosis (FSGS) with intensive
proteinuria, progressive type [23]. The pathogenesis of
the NS has an immunological basis and might be due
to the presence of a circulating factor. This is entirely
compatible with an immunological hypothesis, in that
the factor(s) might be produced by cells of the immune
system, either as the result of immunological reaction
to antigen exposure or due to a primary abnormality of
the immune system itself [24]. 
The aim of this study was to analyse the immuno-
histochemical expression of galectin-3 in renal biopsy
specimens of children with idiopathic (primary)
glomerulopathies.
Patients and Methods
Patients. The study group was composed of children with idio-
pathic nephrotic syndrome (INS), who were treated between 2003
and 2006 in the Department of Paediatric Cardiology and Nephrol-
ogy, Poznan University of Medical Sciences. Two hundred and
eighty-six children were referred to our clinic and evidence of pro-
teinuria was found in 146 of them. Eighty-four patients (44 boys
and 40 girls), following International Study for Kidney Diseases in
Children recommendations, underwent a biopsy [25].  The indica-
tions included: primary idiopathic glomerulonephritis (n=36),
steroid-resistant nephrotic syndrome (SRNS) (n=23) and second-
ary glomerulonephritis (n=25, who were excluded from further
analysis). According to World Health Organization definitions
[25,26], histological evaluation of the study group revealed: mini-
mal change disease (MCD), n=18; diffuse mesangial proliferation
(DMP), n=30; and FSGS, n=11. DMP diagnosis was based on the
number of cells per mesangial area (four and more). INS was clas-
sically characterized by the absence of significant deposits by
immunofluorescence microscopy (IF), except for FSGS and/or
hyalinosis of FSGS, which bound IgM and C3 antiserum. There
was no significant difference between the various categories
defined by IF [26]. In 25 patients with DMP the presence of IgM
and/or IgG within the mesangial area was observed without elec-
tron-dense deposits. No IgA nephropathy was diagnosed in the
subjects. The relevant data are presented in Table 1.
The Ethics Committee of Poznan University of Medical
Sciences approved the research protocol and the parents of all
study participants gave informed consent for the investigation.
Kidney biopsy specimens were fixed in Bouin's solution for 24 h
and subsequently embedded in paraffin.
Controls. Ten age- and sex-matched children in whom total
nephrectomy due to the presence of Wilms tumour had been per-
formed served as a control group. All of these subjects had normal
renal function. Macroscopically normal-appearing kidney tissue
was fixed in Bouin's solution and saved for the subsequent proce-
dure. 
Antibodies and immunohistochemistry. For light microscopy, 6
μm thick sections were dewaxed and processed according to the
indirect avidin-biotin-peroxidase technique [27]. A polyclonal rab-
bit antibody against human galectin-3 (diluted 1:100; Santa Cruz
Biotechnology, sc-20157, Heidelberg, Germany) and monoclonal
mouse anti-CD68 (diluted 1:100; Santa Cruz Biotechnology, sc-
70761, Heidelberg, Germany) were employed. Endogenous perox-
idase reaction was abolished by pre-treatment of the sections with
0.3% H2O2 in phosphate-buffered saline (PBS) prior to incubation
with the antibodies. Following initial incubation with the primary
antibody for 24 h at 4°C, sections were respectively incubated for
1 h at room temperature with goat anti-rabbit IgG (diluted 1:300;
Sigma, Deisenhofen, Germany), goat anti-mouse IgG (diluted
1:300; Santa Cruz Biotechnology, sc-2072, Heidelberg, Germany)
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and then incubated with a streptavidin-biotin-peroxidase reagent
(Vectastain Elite; Vector Laboratories, Burlingame, CA, USA) for
45 min at room temperature. The activity of peroxidase was visu-
alized using 0.5% 3,3'-diaminobenzidine (DAB) in Tris-HCl (pH
7.6) containing 0.3% H2O2 . In all the control samples, the primary
antibody was replaced by a non-immune serum or PBS. Photomi-
crographs were taken using a charge-coupled device (CCD) cam-
era connected to a Nikon Digital Sight S-U1 unit, and the images
were labelled and assembled as plates using Adobe Photoshop 7.0.
Double  immunofluorescence. Some sections were double-
labelled to confirm the identity of cells that were positive or nega-
tive for galectin-3 in the renal corpuscles. For this reason, a double
immunofluorescence protocol was performed. Paraffin sections
were dewaxed and incubated with mouse monoclonal anti-
galectin-3 antibodies (diluted 1:10; Santa Cruz Biotechnology, sc-
32790, Heidelberg, Germany) at 4°C overnight, followed by goat
anti-mouse Alexa Flour 555 secondary antibody (1:200; Molecular
Probes, MobiTec, Goettingen, Germany) at 37°C for 1 h. Subse-
quently, the sections were incubated with polyclonal rabbit anti-
podocalyxin antibodies (1:600; a kind gift from Dr M. G. Farquhar,
San Diego, CA, USA) at 37°C for 1 h, followed by incubation with
Alexa Flour 488 goat anti-rabbit secondary antibody (1:200;
Molecular Probes, MobiTec, Goettingen, Germany) for 30 min at
37°C, The sections were then mounted in buffered glyceringelatin.
These were observed with an Olympus BX60 microscope. Pictures
were taken using a CCD camera connected to Analysis Soft-Imag-
ing System (Muenster, Germany).
Quantitative and statistical  analysis. Due to the limited materi-
al provided by the clinical biopsies, we were not able to assess all
serial sections of individual glomeruli. Instead, we measured the
area of immunoreactive cells within a colour spectrum specific for
the DAB staining and determined the value of at least five
glomeruli in four subsequent sections as a percentage of the whole
glomerular area. Based on the morphological heterogeneity of
glomeruli, which displayed various stages of the respective patho-
logical lesions, we analysed all available glomeruli which met
either DMP or FSGS criteria (Table 1). Variations in antigen distri-
bution within renal glomeruli were evaluated using Micro Image
v.4.0 software (Olympus, MS Windows XP), measuring the area of
marker expression on each colour image by using the 'eye-dropper'
tool for each group of patients. Estimates of galectin-3 expression
were subjected to mathematical analysis in order to examine
changes of these markers in certain glomerulopathies. Differences
between groups were then evaluated by one-way analysis of vari-
ance test (ANOVA). To determine the significance of between
group means in the analysis of variance, the nearest significant dif-
ference test (Tukey test) was used as the multiple comparison
analysis. Significance was set at p<0.05 [28]. Finally, the analysis
was performed blind on coded samples.
Results
Clinical  course
As regarded to the clinical course of nephrotic syn-
drome, there was no correlation between galectin-3
expression and age or sex. There were, however, sig-
nificant differences in galectin-3 tissue localization
between patients with proteinuria who did and did not
respond to steroid therapy. In the former group, con-
sisting of all MCD and DMP patients sensitive to
steroids (DMP-s), galectin-3 was expressed within
individual cortical collecting ducts and distal tubules
as well as thin and thick limbs of loop of Henle and
medullary collecting ducts. It was not present within
renal corpuscles. The latter group of children, consist-
ing of 12 DMP patients resistant to steroids (DMP-r)
and all the FSGS children who developed an
unfavourable clinical course of INS, revealed
immunohistochemical expression of galectin-3 within
all the mentioned above structures and, additionally,
glomeruli (p<0.001). Detailed information is presented
in Table 1.
Bright  field  microscopy
In the control and MCD children (Fig. 1a), anti-
galectin-3 reactivity was present both in renal cortex
and medulla. Within the cortical region it was the
strongest within cortical collecting ducts and 
subjectively less expressed in distal tubules (Fig. 1b).
Its expression was found within cell cytoplasm and
nuclei of numerous, but not all, epithelial cells. The
lining of proximal convoluted tubules softly expressed
galectin-3. Glomerular area was free of galectin-3
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Table 1. Clinical and biochemical characteristics of the study population at the time of kidney biopsy.
reactivity (Fig. 1c). On the other hand galectin-3
immunohistochemical  presence was also found in
both thin and thick limbs of loop of Henle and collect-
ing ducts within renal medulla (Figs. 2a-2c). The same
galectin-3 pattern was observed in all the DMP-s chil-
dren. (Figs. 1d-1f). However, in subjects who did not
responded to steroid therapy (both DMP-r and all the
FSGS), the total number of galectin-3 positive cortical
and medullar segments of collecting ducts (counted as
a number of cross-sected structures per square area)
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Fig. 1. Immunoreactivity for galectin-3 in renal glomeruli of children (scale bar: 800 μm in a, d, g, k; 200 μm in h and l; 100 μm in b, e,
i, m; 50 μm c and f). a-c. Nine-year-old child with minimal change disease (MCD). No galectin-3 reactivity could be found in glomeru-
lar area (c). Anti-galectin-3 reactivity is the strongest within cortical collecting ducts (arrow on b) and a subjectively slighter in distal
tubules (arrow on c). d-f. Immunohistochemical expression of galectin-3 in a 5-year-old child with diffuse mesangial proliferation sensi-
tive to steroids (DMP-s). Galectin-3 is expressed within cortical collecting ducts (arrow on e) and distal tubules (arrow on f). No galectin
reactivity could be found in glomerular area (f). Notice galectin-3 negative cortical collecting ducts (asterisks on e). g-i. Glomerulus of a
7-year-old patient with diffuse mesangial proliferation resistant to steroids (DMP-r). Immunohistochemical reactivity of galectin-3 is pres-
ent not only in cortical collecting ducts (arrow on h) and distal tubules (arrow on i) but also within nuclei of individual mesangial cells
(arrowheads on i). Notice a higher expression of immunoreactive tubules in this specimen (g) as compared to a and d. k-m. Immunoreac-
tivity of a galectin-3 in a 12-year-old-patient with focal segmental glomerulosclerosis (FSGS). Immunohistochemical expression of
galectin-3 is present in cortical collecting ducts (arrow on l), distal tubules (arrow on m) and nuclei of individual mesangial cells (arrow-
heads on m). Notice a higher expression of immunoreactive tubules in this specimen (k) as compared to a and d. The lining of proximal
convoluted tubules is slightly positive (asterisks on m)
was significantly higher (p=0.0045; Figs. 1g, 1h, 1k
and 1l). Interestingly, these patients revealed also
immunohistochemical reactivity of galectin-3 within
nuclei of individual mesangial cells (p<0.001, Figs. 1i
and 1m). CD68 was primarily found in areas of the
interstitial inflammatory infiltration (Fig. 3a) suggest-
ing the presence of macrophages. Its localisation, how-
ever, was independent from age, sex, or type of
glomerulopathy .and was never followed by co-exis-
tence with galectin-3 (Figs 3a-3d).
Double  immunofluorescence  microscopy
In double incubations with anti-galectin-3 and anti-
podocalyxin the analysed markers did not reveal co-
localization in renal glomeruli (Fig. 4). The expression
of podocalyxin was present in podocytes of all the
children. Galectin-3 was not expressed in intra-
glomerular structures of controls, MCD and DMP-s
(data not shown). Its expression was exclusively pres-
ent in the nuclei of individual cells (mesangial cells)
situated in the closest proximity of glomerular capil-
laries of DMP-r and FSGS subjects who did not
respond to steroid therapy.
Discussion
Functional properties of galectin-3 strongly suggest its
importance in the regulation of the immune response
and inflammation (review in [1]). In general, galectin-
3 is a powerful pro-inflammatory signal protein. Cer-
tain cells produce and secrete a large amount of
galectin-3 as a response to various inflammatory stim-
uli. When secreted or externalized, galectin-3 may
affect inflammatory cells by an autocrine or paracrine
mechanism [review in [6]); it promotes adhesion of
human neutrophils to laminin [29] as well as endothe-
lial cells [30] and acts as a chemoattractant for mono-
cytes and macrophages [31]. Galectins, in general, are
not expressed or expressed at lower levels in resting
lymphoid cells [8,32,33]. Infection and transformation
of T cells with human T lymphotropic virus-1 or
human immunodeficiency virus type 1 result in
increased levels of galectin-3 [34]. Interestingly,
galectin-3, which was previously known as Mac-2,
could be identified on the cell surface of mouse peri-
toneal macrophages, and is considered as a marker for
certain mature macrophages [7]. In humans, the
galectin-3 level increases dramatically when mono-
cytes differentiate into macrophages [35]. It is also
expressed in mast cells [36], neutrophils [37] and
eosinophils [38]. In line with this, galectin-3 is sug-
gested to be a positive regulator of T-cell growth [39].
What is more, galectin-3 was also documented as an
anti-apoptotic factor [40,41]. It has been found to
interact with a number of proteins implicated in apop-
tosis regulation (Bcl-2, Fas receptor) [41,42]. It
appears that galectin-3 localized in the cytosol protects
the cell from apoptosis, but localized in nucleus has an
opposite effect (reviewed in [1]). 
Results of the present report have to be discussed in
two different aspects. First, as intraglomerular
galectin-3 expression; secondly as its presence in
extraglomerular area (both cortical and medullar).
Glomerular expression of galectin-3 was found
exclusively in a few FSGS and DMP proteinuric sub-
jects who did not respond to steroid therapy. Accord-
ing to the double immunofluorescence assay and the
subsequent incubations with CD68, the cells reactive
for galectin-3 were recognized as mesangial cells.
They were not co-localised with podocalyxin – a
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Fig. 2. Immunohistochemical expression of galectin-3 in the kid-
ney medulla of a 7-year-old child diagnosed with DMP and steroid
resistant nephrotic syndrome (scale bar 800 μm in a; 200 μm in b;
50 μm in c). Galectin-3 immunoreactivity is present within thin
and thick limbs of loop of Henle (arrows on c), medullary collect-
ing ducts (arrowhead on c). Blood capillaries are galectin-3 nega-
tive (asterisks on c).
marker of podocyte foot processes surface surround-
ing capillaries [20] and were situated outside the
blood vessels. That localisation refers to another
remarks of galectin-3 distribution observed in a rat
model of acute mesangial proliferative glomeru-
lonephritis [14]. Interestingly, galectin-3 positive
mesangial cells in FSGS children were present exclu-
sively within approx. 15% of glomeruli which did not
reveal sclerotic features. The rest of glomeruli (85%)
was galectin-3 negative. It is in line with our another
observation where four of DMP-r patients have
underwent the kidney re-biopsy within 3 years of
observation; all of these were diagnosed at that
moment with FSGS and, curiously, had galectin-3
immuno-negative glomerular pattern. 
In the study demonstrated by Kikuchi Y et al. the
number of galectin-3-positive cells in human diabet-
ic glomeruli significantly increased compared with
other glomerular diseases [18]. In that report, most
galectin-3-positive cells in all glomerular disorders
were also stained with CD68 and HLA-DR, suggest-
ing that these cells are activated macrophages [18]. It
was also insinuated that infiltrated macrophages in
kidneys might play an important role in the progres-
sion of IgA nephropathy, crescent glomerulonephritis
and other renal diseases [43,44]. Moreover, 
the glomerular infiltration of macrophages in diabet-
ic kidneys was thought also to play a crucial role in
the progression of nephropathy. Our results indicate
that both glomerular or extraglomerular galectin-3
positive cells were never co-expressed with CD68.
This may suggest that, contrary to the general point
of view, activated macrophages do not always need
express galectin-3. Interestingly, glomerular galectin-
3 was expressed exclusively in the nuclei of mesan-
gial cells suggesting its pro-apoptotic role. In our 
previous study involving galectin-1 expression in
childhood glomerulopathies, it was detected in renal
podocytes in DMP and FSGS cases, while control
glomeruli and MCD were negative [20]. Galectin-1
immunoreactivity was found also within parietal
epithelial cells in patients with FSGS. These results
suggested a possible role for galectin-1 in the patho-
genesis of primary glomerulopathies in children as a
kind of podocyte-related self-protective activity and
probably involvement of epithelial cells of Bowman's
capsule in inflammatory processes [20]. It seems to
be possible that the similar action implied in our pres-
ent report might insinuate a similar self-protective
activity according to mesangial cells.  On the other
hand, it should result in a more favourable clinical
course. Why then these patients developed resistant
to steroids proteinuria?
This apparent discrepancy might not be logically
explained unless we comment a second aspect of
galectin-3 expression present in collecting ducts, loop
of Henle and distal tubules. That localisation of
galectin-3 and its possible significance in the urinary
system was primarily described on animal model. It is
generally believed that the expression of galectin-3 in
the kidney occurs predominantly during early develop-
mental stages [45,46]. The expression level in the
developing mouse kidney is reduced sharply after
birth, suggesting that the main role of galectin-3 is
related to nephrogenesis; for example, galectin-3 func-
tions as a negative regulator of growth and maturation
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Fig. 3. Immunohistochemical expres-
sion of CD68 (a and b) and galectin-3 (c
and d) in the kidney of an 8-year-old
child diagnosed with DMP and steroid
resistant nephrotic syndrome (scale bar
200 μm  in a and b; 100 μm in c and
d).CD68-positive cells (macrophages)
are found primarily in areas of the inter-
stitial inflammatory infiltration (a).
They are not co-localised with galectin-
3 immunoreactive cells (b). Similarly,
CD68-positive macrophages, if present
within glomerulus (c) are not galectin-3
positive (d). 
of the uretic tree [45,47] or, as described above, pro-
apoptotic factor. Single remarks indicate also a consid-
erably high expression level of galectin-3 in the mouse
adult kidney at the mRNA and protein levels [48].
Immunohistochemically, it was predominantly
expressed in the cortical collecting ducts and the con-
necting segments. The galectin-3 expression in the
renal medulla of adult mice was less intense and was
mainly localized in the medullary and papillary col-
lecting ducts. This was in contrast to the finding in the
developing human kidney, where the most intense
immunoreactivity for galectin-3 was found in
medullary and papillary collecting ducts rather than
cortical collecting ducts [49]. 
In our study, a significantly higher number (den-
sity) of immunopositive tubules (loop o Henle, distal
tubules and collecting ducts) was found in steroid-
resistant individuals (Fig. 1g and 1k). A 'tiger-like'
pattern of galectin-3 immunoreactivity in cortical
collecting ducts and distal convoluted tubules with
its subsequent expression in cytoplasm or nuclei
(Fig. 1i and 1m) we would brave to interpret as a
populations of epithelial cells which are, in galecin-
3 dependent manner, forced into reconstruction. It
then maybe followed by certain perturbation of pep-
tides re-absorption or addition their secretion result-
ing in resistant to steroid but glomerularly independ-
ent proteinuria.
In line with above, a suggested galectin-3 authority
in mature human glomeruli during proteinuric
glomerulopathies may indicate, on the one hand, its
anti-inflammatory effect, but on the other can prog-
nosticate a further glomerular reconstruction leading
to FSGS. The areas of sclerosis in FSGS and objec-
tively decreased glomerular cellularity may explain
why these structures are galectin-3 negative. Taken
together, both glomerular and extraglomerular
galectin-3 immunoreactivity in certain DMP individu-
als could be regarded as the factor of unfavourable
prognosis. 
Acknowledgements: The authors thank Mrs S. Bramke (from
Department of Anatomy, Technical University in Dresden, Ger-
many) for her skilful technical work. They also thank Professor
Geoffrey Shaw for his assistance with the English text. The authors
are indebted to Dr Aldona Wozniak for helpful discussions. 
This study was supported by the State Committee for Scientific
Research (KBN, grant no. 0060/B/P01/2008/35).
Conflict of interest statement The corresponding (on behalf of
all authors in the paper) reveals any 1) financial interests or
arrangements with a company whose product was used in a study
or is referred to in a manuscript, 2) any financial interests of
arrangement with a competing company, 3) any direct payment to
an author(s) from any source for the purpose of writing the man-
uscript, and 4) any other financial connections, direct or indirect,
or other situations that might raise the question of bias in the
work reported or the conclusions, implications, or opinions stat-
ed – including pertinent commercial or other sources of funding
for the individual author(s) or for the associated department(s) or
organization(s), personal relationships, or direct academic com-
petition.
References
[ 1] Dumic J, Dabelic S, Floegel M. Galectin-3: an open-ended
story. Biochim Biophys Acta. 2006;1760:616-635. 
[ 2] Liu FT. Regulatory roles of galectins in the immune response.
Int Arch Allergy Immunol. 2005;136:385-400.
[ 3] Hsu DK, Zuberi RI, Liu FT. Biochemical and biophysical
characterization of human recombinant IgE-binding protein,
an S-type animal lectin. J Biol Chem. 1992;267:14167-14174.
[ 4] Agrwal N, Sun Q, Wang SY and Wang JL. Carbohydrate-
binding protein 35. I. Properties of the recombinant polypep-
tide and the individuality of the domains. J Biol Chem.
1993;268:14932-14939.
[ 5] Mehul B, Bawumia S, Martin SR and Hughes RC. Structure
of baby hamster kidney carbohydrate-binding protein CBP30,
an S-type animal lectin. J Biol Chem. 1994;269:18250-18258.
[ 6] van den Brule F, Califice S, Castronovo V. Expression of
galectins in cancer: a critical review. Glycoconj J.
2004;19:537-542.
[ 7] Ho MK, Springer TA. Mac-2, a novel 32,000 Mr mouse
macrophage subpopulation-specific antigen defined by mon-
oclonal antibodies. J Immunol. 1982;128:1221-1228.
[ 8] Joo HG , Goedegebuure PS, Sadanaga N et al. Expression
and function of galectin-3, a beta-galactoside-binding pro-
tein in activated T lymphocytes. J Leukoc Biol. 2001;69:
555-564.
[ 9] Yu F, Finley RL Jr, Raz A and Kim HR. Galectin-3 translo-
cates to the perinuclear membranes and inhibits cytochrome c
release from the mitochondria. A role for synexin in galectin-
3 translocation. J Biol Chem. 2002;277:15819-15827.
[10] Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3
marks activated macrophages in failure-prone hypertrophied
hearts and contributes to cardiac dysfunction. Circulation.
2004;110:3121-3128.
321Expression of galectin-3
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(2): 321 (315-322) 
10.2478/v10042-009-0069-0
Fig. 4. Double incubation of galectin-3 (red) and podocalyxin
(green) in glomerulus of a 7-year-old child with resistant to
steroids diffuse mesangial proliferation (scale bar 25 μm). The
expression of podocalyxin is present in podocytes (marker of
podocyte foot processes surface surrounding capillaries). Galectin-
3 is expressed in the nuclei of individual mesangial cells situated
in the closest proximity of glomerular capillaries as well as extra-
glomerular tubular cells.
[11] Matarrese P, Fusco O, Tinari N et al. Galectin-3 overexpres-
sion protects from apoptosis by improving cell adhesion prop-
erties, Int J Cancer. 2000;85:545-554.
[12] Ochieng J, Green B, Evans S et al. Modulation of the biolog-
ical functions of galectin-3 by matrix metalloproteinases.
Biochim Biophys Acta. 1998;1379:97-106.
[13] Leffler H, Masiarz FR, Barondes SH. Soluble lactose-binding
vertebrate lectins: a growing family. Biochemistry. 1989;28:
9222-9229.
[14] Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat
mesangial cell proliferation and matrix synthesis during
experimental glomerulonephritis induced by anti-Thy1.1 anti-
bodies. J Pathol. 1999;187:481-489.
[15] Nishiyama J, Kobayashi S, Ishida A et al. Up-regulation of
galectin-3 in acute renal failure of the rat. Am J Pathol.
2000;157:815-823.
[16] Pugliese G, Pricci F, Leto G et al. The diabetic milieu modu-
lates the advanced glycation end product-receptor complex in
the mesangium by inducing or upregulating galectin-3
expression. Diabetes. 2000;49:1249-1257.
[17] Sedivá A, Smetana K Jr, Stejskal J et al. Binding sites for car-
rierimmobilized carbohydrates in the kidney: implication for
the pathogenesis of Henoch-Schoenlein purpura and/or IgA
nephropathy. Nephrol Dial Transplant. 1999;14:2885-2891.
[18] Kikuchi Y, Kobayashi S, Hemmi N et al. Galectin-3-positive
cell infiltration in human diabetic nephropathy. Nephrol Dial
Transplant. 2004;19:602-607.
[19] Saussez S, Nonclercq D, Laurent G et al. Toward functional
glycomics by localization of tissue lectins: immunohisto-
chemical galectin fingerprinting during diethylstilbestrol-
induced kidney tumorigenesis in male Syrian hamster. His-
tochem Cell Biol. 2005;123:29-41.
[20] Ostalska-Nowicka D, Zachwieja J, Nowicki M et al.
Immunohistochemical detection of galectin-1 in renal biopsy
specimens of children and its possible role in proteinuric
glomerulopathies. Histopathology. 2007;51:468-476.
[21] Mundel P, Shankland SJ. Podocyte biology and response to
injury. J Am Soc Nephrol. 2002;13:3005-3015.
[22] Kriz W, Lemley KV. The role of the podocyte in glomeru-
losclerosis. Curr. Opin. Nephrol Hypertens. 1999;8:489-497.
[23] Barratt TM, Clark G. Minimal change nephritic syndrome
and focal segmental glomerulosclerosis. In Holliday MA,
Barratt TM, Ed A eds. Pediatric nephrology, 3rd edn. Balti-
more, MD: Williams & Wilkins, 1994;767-787.
[24] Bakker WW, van Luijk WH. Do circulating factors play a role
in the pathogenesis of minimal change nephrotic syndrome?
Pediatr Nephrol. 1989;3:341-349.
[25] Churg J, Habib R, White RH. Pathology of the nephrotic syn-
drome in children: a report for the International Study of Kid-
ney Disease in Children. Lancet. 1970;760:1299-1302.
[26] Habib R, Girardin E, Gagnadoux MF et al. Immunopatho-
logical findings in idiopathic nephrosis: clinical significance
of glomerular ''immune deposits''. Pediatr Nephrol.
1988;2:402-408.
[27] Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase
complex (ABC) in immunoperoxidase techniques: a compar-
ison between ABC and unlabeled antibody (PAP) procedures.
J Histochem Cytochem. 1981;29:577-580.
[28] Armitage P, Gehan EA. Statistical methods for the identifica-
tion and use of prognostic factors. Int. J Cancer 1974;13:16-36.
[29] Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human
neutrophils to laminin. J Immunol. 1996;156:3939-3944.
[30] Sato S, Ouellet N, Pelletier I et al. Role of galectin-3 as an
adhesion molecule for neutrophil extravasation during strep-
tococcal pneumonia. J Immunol. 2002;168:1813-1822.
[31] Sano H, Hsu DK, Yu L et al. Human galectin-3 is a novel
chemoattractant for monocytes and macrophages. J Immunol.
2000;165:2156-2164.
[32] Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and
macrophage staining by monoclonal antibodies in tissue sec-
tions and epidermal sheets. Am J Pathol. 1983;111:112-124.
[33] Liu FT, Albrandt K, Mendel E et al. Identification of an IgE-
binding protein by molecular cloning. Proc Natl Acad Sci
USA. 1985;82:4100-4104.
[34] Schroder HC, Ushijima H, Theis C et al. Expression of
nuclear lectin carbohydrate-binding protein 35 in human
immunodeficiency virus type 1-infected Molt-3 cells. J. Acquir
Immune Defic Syndr Human Retrovirol. 1995;9:340-348.
[35] Liu FT, Hsu DK, Zuberi RI et al. Expression and function of
galectin-3, a beta-galactoside-binding lectin, in human mono-
cytes and macrophages. Am J Pathol. 1995;147:1016-1028.
[36] Frigeri LG, Zuberi RI, Liu FT. Epsilon BP, a beta-galac-
tosidebinding animal lectin, recognizes IgE receptor (Fc
epsilon RI) and activates mast cells. Biochemistry. 1993;32:
7644-7649.
[37] Truong MJ, Gruart V, Kusnierz JP et al. Human neutrophils
express immunoglobulin E (IgE)-binding proteins (Mac-
2/epsilon BP) of the S-type lectin family: role in IgE depend-
ent activation. J Exp Med. 1993;177:243-248.
[38] Truong MJ, Gruart V, Liu FT et al. IgE binding molecules
(Mac-2/epsilon BP) expressed by human eosinophils. Impli-
cation in IgE-dependent eosinophil cytotoxicity. Eur J
Immunol. 1993;23:3230-3235.
[39] Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modu-
lates T-cell growth and apoptosis. Proc Natl Acad Sci USA.
1996;93:6737-6742.
[40] Yoshii T, Fukumori T, Honjo Y et al. Galectin-3 phosphoryla-
tion is required for its anti-apoptotic function and cell cycle
arrest. J Biol Chem. 2002;277:6852-6857.
[41] Akahani S, Nangia-Makker P, Inohara H et al. Galectin-3: a
novel antiapoptotic molecule with a functional BH1 (NWGR)
domain of Bcl-2 family. Cancer Res. 1997;57:5272-5276.
[42] Fukumori T, Takenaka Y, Oka N et al. Endogenous galectin-
3 determines the routing of CD95 apoptotic signaling path-
ways. Cancer Res. 2004;64:3376-3379.
[43] Hotta O, Yusa N, Ooyama M and Taguma Y. Urinary
macrophage counts and ratio to T lymphocytes: possible use
in differential diagnosis and management of glomerular dis-
ease. J Clin Lab Anal. 1996;10:205-208.
[44] Oda T, Hotta O, Taguma Y et al. Clinicopathological signifi-
cance of intratubular giant macrophages in progressive
glomerulonephritis. Kidney Int. 1998;53:1190-1200.
[45] Bullock SL, Johnson TM, Bao Q et al. Galectin-3 modulates
ureteric bud branching in organ culture of the developing
mouse kidney. J Am Soc Nephrol. 2001;12:515-523.
[46] Hughes RC. Galectins in kidney development. Glycoconj J.
2004;19:621-629.
[47] Chiu MG, Johnson TM, Woolf AS et al. Galectin-3 associates
with the primary cilium and modulates cyst growth in con-
genital polycystic kidney disease. Am J Pathol.
2006;169:1925-1938. 
[48] Nio J, Takahashi-Iwanaga H, Morimatsu M et al. Immuno-
histochemical and in situ hybridization analysis of galectin-3,
a b-galactoside binding lectin, in the urinary system of adult
mice. Histochem Cell Biol. 2006;126:45-56.
[49] Winyard PJ, Bao Q, Hughes RC and Woolf AS. Epithelial
galectin-3 during human nephrogenesis and childhood cystic
diseases. J Am Soc Nephrol. 1997;8:1647-1657.
Submitted: 20 November, 2008
Accepted after revision: 20 February, 2009
322 M. Nowicki et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(2): 322 (315-322) 
10.2478/v10042-009-0069-0
